Preventive Medication Patterns in Bipolar Disorder and Their Relationship With Comorbid Substance Use Disorders in a Cross-National Observational Study.
bipolar disorder
comorbidity
substance use disorder
tobacco smoking
treatment guidelines
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
11
2021
accepted:
11
04
2022
entrez:
20
5
2022
pubmed:
21
5
2022
medline:
21
5
2022
Statut:
epublish
Résumé
The potential role of sub-optimal pharmacological treatment in the poorer outcomes observed in bipolar disorder (BD) with vs. without comorbid substance use disorders (SUDs) is not known. Thus, we investigated whether patients with BD and comorbid SUD had different medication regimens than those with BD alone, in samples from France and Norway, focusing on compliance to international guidelines. Seven hundred and seventy patients from France and Norway with reliably ascertained BD I or II (68% BD-I) were included. Medication information was obtained from patients and hospital records, and preventive treatment was categorized according to compliance to guidelines. We used Bayesian and regression analyses to investigate associations between SUD comorbidity and medication. In the Norwegian subsample, we also investigated association with lack of medication. Comorbid SUDs were as follows: current tobacco smoking, 26%, alcohol use disorder (AUD), 16%; cannabis use disorder (CUD), 10%; other SUDs, 5%. Compliance to guidelines for preventive medication was lacking in 8%, partial in 44%, and complete in 48% of the sample. Compliance to guidelines was not different in BD with and without SUD comorbidity, as was supported by Bayesian analyses (highest Bayes Factor = 0.16). Cross national differences in treatment regimens led us to conduct country-specific adjusted regression analyses, showing that (1) CUD was associated with increased antipsychotics use in France (OR = 2.4, 95% CI = 1.4-3.9, SUD comorbidity in BD was overall not associated with different pharmacological treatment in our sample, and not related to the level of compliance to guidelines. We found country-specific associations between comorbid SUDs and specific medications that warrant further studies.
Identifiants
pubmed: 35592382
doi: 10.3389/fpsyt.2022.813256
pmc: PMC9110763
doi:
Types de publication
Journal Article
Langues
eng
Pagination
813256Informations de copyright
Copyright © 2022 Icick, Melle, Etain, Høegh, Gard, Aminoff, Leboyer, Andreassen, Belzeaux, Henry, Bjella, Kahn, Steen, Bellivier and Lagerberg.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Affect Disord. 2015 Jan 15;171:39-47
pubmed: 25285897
J Clin Psychiatry. 2009 Feb;70(2):171-6
pubmed: 19192456
Aust N Z J Psychiatry. 2018 Sep;52(9):847-855
pubmed: 30047784
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
J Affect Disord. 2008 Sep;110(1-2):126-34
pubmed: 18280579
Am J Drug Alcohol Abuse. 2017 Jul;43(4):366-376
pubmed: 28301219
Am J Psychiatry. 2010 Mar;167(3):289-97
pubmed: 20008948
Psychiatry Investig. 2015 Jul;12(3):349-55
pubmed: 26207128
World J Psychiatry. 2019 Jan 4;9(1):7-29
pubmed: 30631749
J Affect Disord. 2019 Sep 1;256:86-95
pubmed: 31163332
Bipolar Disord. 2000 Jun;2(2):120-30
pubmed: 11252651
Front Psychiatry. 2018 Nov 13;9:575
pubmed: 30483161
Bipolar Disord. 2019 Nov;21(7):595-610
pubmed: 31077521
J Affect Disord. 2018 Dec 1;241:367-370
pubmed: 30144720
J Clin Psychiatry. 2008 Nov;69(11):1751-7
pubmed: 18945397
Psychiatry Res. 2013 Oct 30;209(3):459-65
pubmed: 23312479
Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):1-11
pubmed: 25912533
J Clin Psychopharmacol. 2015 Feb;35(1):68-74
pubmed: 25514063
Expert Opin Drug Saf. 2019 Oct;18(10):893-913
pubmed: 31364895
J Affect Disord. 2021 May 1;286:309-319
pubmed: 33770539
Bipolar Disord. 2018 Mar;20(2):97-170
pubmed: 29536616
JAMA Psychiatry. 2013 Sep;70(9):931-9
pubmed: 23863861
Alcohol Clin Exp Res. 2012 Mar;36(3):490-6
pubmed: 21933201
CNS Spectr. 2019 Dec;24(6):589-596
pubmed: 30905327
BMC Psychiatry. 2013 Aug 13;13:211
pubmed: 23941445
J Affect Disord. 2015 Sep 01;183:113-8
pubmed: 26001671
J Clin Psychiatry. 2021 Jun 1;82(3):
pubmed: 34077034
Aust N Z J Psychiatry. 2015 Oct;49(10):898-905
pubmed: 25991763
Clin Psychol Psychother. 2017 Jul;24(4):887-898
pubmed: 27761983
J Nerv Ment Dis. 2010 May;198(5):370-2
pubmed: 20458200
Am J Addict. 2018 Apr;27(3):188-201
pubmed: 29596721
Harv Rev Psychiatry. 2019 Sep/Oct;27(5):290-302
pubmed: 31385812
Psychon Bull Rev. 2018 Feb;25(1):128-142
pubmed: 28251595
J Nerv Ment Dis. 2011 Apr;199(4):239-43
pubmed: 21451347
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
J Affect Disord. 2016 Dec;206:331-349
pubmed: 27476137
Addiction. 2017 Jul;112(7):1250-1259
pubmed: 28192643
J Affect Disord. 2013 Jun;148(2-3):375-83
pubmed: 23414573
J Affect Disord. 2020 Apr 15;267:258-263
pubmed: 32217226
J Affect Disord. 2013 Dec;151(3):1009-15
pubmed: 24051101
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 8;89:84-89
pubmed: 30153497
Nicotine Tob Res. 2017 Sep 01;19(9):1107-1111
pubmed: 28339973
BMC Health Serv Res. 2017 Feb 7;17(1):119
pubmed: 28173867
BJPsych Open. 2020 Nov 06;6(6):e138
pubmed: 33153508
Neuropsychiatr Dis Treat. 2020 Mar 26;16:815-828
pubmed: 32273708
J Affect Disord. 2016 Dec;206:321-330
pubmed: 27426694
J Affect Disord. 2016 May;195:50-6
pubmed: 26859073
Depress Anxiety. 2021 Feb;38(2):114-123
pubmed: 32598093
J Affect Disord. 2019 Sep 1;256:348-357
pubmed: 31202989
Eur Addict Res. 2014;20(1):41-8
pubmed: 23921461
J Clin Med. 2018 Jan 30;7(2):
pubmed: 29385731
Curr Neuropharmacol. 2017 Apr;15(3):409-416
pubmed: 28503113
Psychiatr Serv. 2007 Jan;58(1):85-91
pubmed: 17215417
J Affect Disord. 2010 Aug;124(3):250-5
pubmed: 19959240
Lancet Psychiatry. 2015 Sep;2(9):801-8
pubmed: 26277044
J Affect Disord. 2016 May;195:105-18
pubmed: 26881339
Front Psychiatry. 2021 Mar 23;12:660432
pubmed: 33833701
Int J Bipolar Disord. 2013 May 03;1:5
pubmed: 25505672
Eur Arch Psychiatry Clin Neurosci. 1999;249(4):174-9
pubmed: 10449592
J Psychiatr Pract. 2011 Jan;17(1):5-20
pubmed: 21266890
J Affect Disord. 2016 Jan 15;190:286-293
pubmed: 26544611
Handb Exp Pharmacol. 2018;252:143-164
pubmed: 29633178
Schizophr Res. 2000 May 5;42(3):241-7
pubmed: 10785582
Actas Esp Psiquiatr. 2016 Nov;44(6):222-30
pubmed: 27906413
Curr Psychiatry Rep. 2015 Feb;17(2):4
pubmed: 25617040
Acta Psychiatr Scand. 2014 May;129(5):366-74
pubmed: 23865756
Fed Pract. 2017 Mar;34(Suppl 2):37S-41S
pubmed: 30766306
J Clin Psychopharmacol. 2016 Aug;36(4):355-71
pubmed: 27307187
J Affect Disord. 2020 Jul 1;272:326-334
pubmed: 32553374
Psychiatry Clin Neurosci. 2020 Aug;74(8):418-423
pubmed: 32306467
Am J Psychiatry. 2007 Jan;164(1):100-7
pubmed: 17202550
J Affect Disord. 2021 Sep 1;292:352-358
pubmed: 34139408